HRP20140759T1 - Kompozicije za lijeäśenje središnje posredovane muäśnine i povraä†anja - Google Patents

Kompozicije za lijeäśenje središnje posredovane muäśnine i povraä†anja Download PDF

Info

Publication number
HRP20140759T1
HRP20140759T1 HRP20140759AT HRP20140759T HRP20140759T1 HR P20140759 T1 HRP20140759 T1 HR P20140759T1 HR P20140759A T HRP20140759A T HR P20140759AT HR P20140759 T HRP20140759 T HR P20140759T HR P20140759 T1 HRP20140759 T1 HR P20140759T1
Authority
HR
Croatia
Prior art keywords
netupitant
combination
use according
administered
pharmaceutically acceptable
Prior art date
Application number
HRP20140759AT
Other languages
English (en)
Croatian (hr)
Inventor
Fabio Trento
Sergio Cantoreggi
Giorgia Rossi
Roberta Cannella
Daniele Bonadeo
Riccardo Braglia
Original Assignee
Helsinn Healthcare S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43608757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20140759(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare S.A. filed Critical Helsinn Healthcare S.A.
Publication of HRP20140759T1 publication Critical patent/HRP20140759T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Paints Or Removers (AREA)
  • Medicines Containing Plant Substances (AREA)
HRP20140759AT 2009-11-18 2010-11-18 Kompozicije za lijeäśenje središnje posredovane muäśnine i povraä†anja HRP20140759T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26247009P 2009-11-18 2009-11-18
US38270910P 2010-09-14 2010-09-14
PCT/IB2010/003106 WO2011061622A1 (en) 2009-11-18 2010-11-18 Compositions for treating centrally mediated nausea and vomiting

Publications (1)

Publication Number Publication Date
HRP20140759T1 true HRP20140759T1 (hr) 2014-10-24

Family

ID=43608757

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20140759AT HRP20140759T1 (hr) 2009-11-18 2010-11-18 Kompozicije za lijeäśenje središnje posredovane muäśnine i povraä†anja
HRP20161277TT HRP20161277T1 (hr) 2009-11-18 2016-10-05 Pripravci za liječenje centralno posredovane mučnine i povraćanja
HRP20170419TT HRP20170419T1 (hr) 2009-11-18 2017-03-14 Sastavi za liječenje središnje posredovane mučnine i povraćanja

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20161277TT HRP20161277T1 (hr) 2009-11-18 2016-10-05 Pripravci za liječenje centralno posredovane mučnine i povraćanja
HRP20170419TT HRP20170419T1 (hr) 2009-11-18 2017-03-14 Sastavi za liječenje središnje posredovane mučnine i povraćanja

Country Status (40)

Country Link
US (1) US12042494B2 (enExample)
EP (3) EP2727590B1 (enExample)
JP (1) JP5890780B2 (enExample)
KR (1) KR101615108B1 (enExample)
CN (6) CN104856998A (enExample)
AP (1) AP3083A (enExample)
AU (1) AU2010320598B2 (enExample)
BR (1) BR112012011485B1 (enExample)
CA (1) CA2778301C (enExample)
CL (1) CL2012001276A1 (enExample)
CO (1) CO6551693A2 (enExample)
CR (1) CR20120216A (enExample)
CU (1) CU24048B1 (enExample)
CY (1) CY1118062T1 (enExample)
DK (2) DK2722045T3 (enExample)
DO (1) DOP2012000138A (enExample)
EA (1) EA026815B1 (enExample)
EC (1) ECSP12011907A (enExample)
ES (4) ES2623503T3 (enExample)
GE (1) GEP20156226B (enExample)
GT (1) GT201200156A (enExample)
HK (2) HK1214148A1 (enExample)
HR (3) HRP20140759T1 (enExample)
HU (1) HUE029677T2 (enExample)
IL (1) IL219576A (enExample)
LT (1) LT2722045T (enExample)
MA (1) MA33810B1 (enExample)
MX (1) MX2012005347A (enExample)
MY (1) MY159393A (enExample)
NI (1) NI201200090A (enExample)
NZ (1) NZ599439A (enExample)
PE (1) PE20121483A1 (enExample)
PH (1) PH12012500887A1 (enExample)
PL (3) PL2361090T3 (enExample)
PT (2) PT2722045T (enExample)
RS (2) RS53491B1 (enExample)
SI (2) SI2722045T1 (enExample)
SM (1) SMT201400112B (enExample)
TN (1) TN2012000170A1 (enExample)
WO (1) WO2011061622A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
ES2623503T3 (es) 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente
ES2672099T3 (es) * 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
JP2014530249A (ja) * 2011-10-18 2014-11-17 ヘルシン ヘルスケア ソシエテ アノニム ネツピタントおよびパロノセトロンの治療学的組合せ
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
CN103520725B (zh) * 2012-07-05 2017-10-24 海思科医药集团股份有限公司 一种治疗呕吐的药物组合物
BR112017018620A2 (pt) 2015-03-04 2018-04-17 Vanda Pharmaceuticals Inc. método de administração de tradipitanto, e, tradipitanto.
CN106902086B (zh) * 2015-12-23 2020-10-20 江苏恒瑞医药股份有限公司 一种包含奈妥匹坦的固体组合物
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN108721214B (zh) * 2017-04-14 2020-06-16 和龙 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
CN108853010A (zh) * 2017-05-15 2018-11-23 和龙 奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途
CN109200018A (zh) * 2017-07-04 2019-01-15 南京诺瑞特医药科技有限公司 含有奈妥吡坦的微乳制剂
CN119074729A (zh) * 2017-11-17 2024-12-06 万达制药公司 使用川地匹坦治疗胃肠疾病的方法
WO2019148247A1 (en) * 2018-02-02 2019-08-08 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Oral formulations and uses thereof
WO2024126408A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Antioxidant-free fixed dose combination of netupitant and palonosetron
IL321446A (en) 2022-12-12 2025-08-01 Tiefenbacher Alfred E Gmbh & Co Kg Fixed-dose combination including netopitant and flunosterone
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0430190T3 (da) 1989-11-28 1995-08-21 Syntex Inc Hidtil ukendte tricykliske forbindelser
US5510486A (en) 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US6297395B1 (en) 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
PT1035115E (pt) 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
ATE400556T1 (de) 2000-07-14 2008-07-15 Hoffmann La Roche N-oxide als nk1-rezeptorantagonistenprodrugs von 4-phenylpyridinderivaten
AU1608502A (en) 2000-12-14 2002-06-24 Hoffmann La Roche Self emulsifying lipid matrix (selm)
JP5690461B2 (ja) 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
TWI355936B (en) 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
CA2521369A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ.ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
US7479312B2 (en) 2005-07-07 2009-01-20 Konica Minolta Opto, Inc. Retardation film, polarizing plate, and liquid crystal display device
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
EA200801738A1 (ru) * 2006-02-23 2008-12-30 Пфайзер Лимитед Пиперидиноилпирролидиновые агонисты меланокортинового рецептора 4 типа
ES2325339T3 (es) * 2006-10-24 2009-09-01 Helsinn Healthcare S.A. Capsulas blandas que comprenden hidrocloruro de palonosetron que tienen una estabilidad y una biodisponibilidad mejoradas.
US20110014117A1 (en) * 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
EP2247757A2 (en) * 2007-12-18 2010-11-10 Schering Corporation Biomarkers for sensitivity to anti-igf1r therapy
ES2623503T3 (es) 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente

Also Published As

Publication number Publication date
US12042494B2 (en) 2024-07-23
PL2361090T3 (pl) 2014-10-31
WO2011061622A1 (en) 2011-05-26
CN104856999A (zh) 2015-08-26
US20230263799A1 (en) 2023-08-24
CO6551693A2 (es) 2012-10-31
BR112012011485A2 (pt) 2018-04-03
PH12012500887A1 (en) 2016-08-26
NI201200090A (es) 2012-11-13
CN106421793B (zh) 2023-06-16
EA201290356A1 (ru) 2012-12-28
CA2778301A1 (en) 2011-05-26
GT201200156A (es) 2014-03-27
CL2012001276A1 (es) 2012-12-07
CU24048B1 (es) 2014-12-26
CN106421793A (zh) 2017-02-22
RS53491B1 (sr) 2015-02-27
ES2559475T3 (es) 2016-02-12
PE20121483A1 (es) 2012-12-02
EP2361090A1 (en) 2011-08-31
EP2722044A1 (en) 2014-04-23
GEP20156226B (en) 2015-01-26
CN107050455A (zh) 2017-08-18
NZ599439A (en) 2014-06-27
TN2012000170A1 (en) 2013-12-12
SI2722045T1 (sl) 2017-02-28
BR112012011485B1 (pt) 2021-06-29
CY1118062T1 (el) 2017-06-28
DOP2012000138A (es) 2012-11-15
DK2361090T3 (da) 2014-08-25
PL2722045T3 (pl) 2017-03-31
PT2722045T (pt) 2016-10-18
MX2012005347A (es) 2012-08-03
HUE029677T2 (hu) 2017-03-28
CU20120078A7 (es) 2012-10-15
CN104856998A (zh) 2015-08-26
CN107050455B (zh) 2020-09-29
EP2727590B1 (en) 2015-10-21
HRP20161277T1 (hr) 2016-11-18
CR20120216A (es) 2012-07-24
EP2722044B1 (en) 2017-01-04
IL219576A (en) 2017-08-31
EP2727590A1 (en) 2014-05-07
AU2010320598B2 (en) 2016-06-16
JP2013511507A (ja) 2013-04-04
SI2361090T1 (sl) 2014-09-30
KR101615108B1 (ko) 2016-05-12
HK1214148A1 (zh) 2016-07-22
HRP20170419T1 (hr) 2017-06-02
EA026815B1 (ru) 2017-05-31
SMT201400112B (it) 2014-11-10
PL2722044T3 (pl) 2017-08-31
MA33810B1 (fr) 2012-12-03
ES2595077T3 (es) 2016-12-27
AU2010320598A1 (en) 2012-06-14
MY159393A (en) 2016-12-30
EP2361090B1 (en) 2014-05-21
LT2722045T (lt) 2016-09-26
CA2778301C (en) 2016-06-14
HK1214147A1 (zh) 2016-07-22
CN106512010A (zh) 2017-03-22
JP5890780B2 (ja) 2016-03-22
ES2494015T3 (es) 2014-09-12
ECSP12011907A (es) 2012-10-30
RS55206B1 (sr) 2017-01-31
AP2012006278A0 (en) 2012-06-30
AP3083A (en) 2015-01-31
IL219576A0 (en) 2012-06-28
ES2623503T3 (es) 2017-07-11
DK2722045T3 (en) 2016-10-24
KR20120101456A (ko) 2012-09-13
CN102655864A (zh) 2012-09-05
PT2361090E (pt) 2014-09-03

Similar Documents

Publication Publication Date Title
HRP20140759T1 (hr) Kompozicije za lijeäśenje središnje posredovane muäśnine i povraä†anja
US8058291B2 (en) Methods and compositions for the treatment of CNS-related conditions
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
JP2009525343A5 (enExample)
JP2010174019A5 (enExample)
JP2023537840A (ja) ナビロンを単独及びカンナビノイドと併用する経皮製剤
HRP20240121T1 (hr) Kontracepcija na bazi drospirenona za pacijenticu s viškom tjelesne težine
JP2017531033A5 (enExample)
HRP20241360T1 (hr) Optimirano doziranje diaminofenotiazina u populacijama
JP2018527305A5 (enExample)
JP2013500943A5 (enExample)
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
HRP20171922T1 (hr) Farmaceutski pripravak koji sadrži (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano [3,4,b]indol]-4-amin i duloksetin
RU2017136693A (ru) Способы поддержания, лечения или улучшения когнитивной функции
RU2015128914A (ru) Составы лоразепама с контролируемым высвобождением
RU2013124994A (ru) КОМБИНАЦИЯ БЕВАЦИЗУМАБА И 2,2-ДИМЕТИЛ-N-((S)-6-ОКСО-6,7-ДИГИДРО-5Н-ДИБЕНЗО[b,d]АЗЕПИН-7-ИЛ)-N'-(2,2,3,3,3-ПЕНТАФТОР-ПРОПИЛ)-МАЛОНАМИДА ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
RU2500399C2 (ru) Комбинированное анальгезирующее и спазмолитическое средство
HRP20171927T1 (hr) Farmaceutski pripravak koji sadrži (1r,4r)-6'-fluor-n,n-dimetil-4-fenil-4',9'-diidro-3'h-spiro[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amin i acetilsalicilnu kiselinu
HRP20200155T1 (hr) Farmaceutski pripravak koji obuhvaća drospirenon i kontracepcijski komplet
RU2018132042A (ru) Применение ингибиторов активности или функции pi3k для лечения первичного синдрома шегрена
NZ739195B2 (en) Drospirenone-based contraceptive for a female patient affected with excess weight
RU2004108632A (ru) Композиция для лечения аллергических заболеваний, и способ ее промышленного получения